Abstract
Sunitinib is a multi-targeted tyrosine kinase inhibitor widely used in clear cell renal carcinoma and in imatinib-resistant gastrointestinal stromal tumors. Sunitinib-associated cardiotoxicity has been recognized and includes hypertension, left ventricular dysfunction and congestive heart failure; nevertheless, few data exist in the literature regarding the role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity. We report a case of sunitinib-induced severe left ventricular dysfunction that occurred in a hypertensive woman with metastatic renal carcinoma and a history of preeclampsia, and a case of sunitinib-induced preeclampsia-like syndrome in a normotensive patient with an imatinib-resistant gastrointestinal stromal tumor. Our experience confirms that inhibition of angiogenic factors to treat cancer is a novel challenge for the oncologist and requires the cardiologist's support.
MeSH terms
-
Adult
-
Angiogenesis Inducing Agents / metabolism*
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects*
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Renal Cell / drug therapy
-
Fatal Outcome
-
Female
-
Gastrointestinal Stromal Tumors / drug therapy
-
Humans
-
Indoles / administration & dosage
-
Indoles / adverse effects*
-
Indoles / therapeutic use
-
Middle Aged
-
Pre-Eclampsia / chemically induced*
-
Pre-Eclampsia / diagnosis
-
Pre-Eclampsia / drug therapy
-
Pre-Eclampsia / metabolism*
-
Pregnancy
-
Pyrroles / administration & dosage
-
Pyrroles / adverse effects*
-
Pyrroles / therapeutic use
-
Sunitinib
-
Ventricular Dysfunction, Left / chemically induced*
-
Ventricular Dysfunction, Left / diagnosis
-
Ventricular Dysfunction, Left / drug therapy
Substances
-
Angiogenesis Inducing Agents
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Indoles
-
Pyrroles
-
Sunitinib